Depomed Inc (DEPO): Thadd M Vargas , Senior VP, BD of Depomed Inc sold 15,000 shares on May 23, 2016. The Insider selling transaction was reported by the company on May 25, 2016 to the Securities and Exchange Commission. The shares were sold at $20.00 per share for a total value of $300,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 10, 2016, Thadd M Vargas (Senior VP, BD) sold 15,000 shares at $17.64 per share price.On May 9, 2016, August J Moretti (Chief Financial Officer & SVP) sold 5,000 shares at $18.00 per share price.
Depomed Inc: On Friday, May 20, 2016 heightened volatility was witnessed in Depomed Inc which led to swings in the share price. The shares opened for trading at $19.11 and hit $19.94 on the upside , eventually ending the session at $19.92, with a gain of 4.29% or 0.82 points. The heightened volatility saw the trading volume jump to 15,77,138 shares. The 52-week high of the share price is $33.74 and the company has a market cap of $1,217,072 M . The 52-week low of the share price is at $12.25.
Company has been under the radar of several Street Analysts.Depomed Inc is Upgraded by Mizuho to Buy and the brokerage firm has set the Price Target at $19. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 9, 2016.Depomed Inc is Reiterated by Mizuho to Neutral and the brokerage firm has raised the Price Target to $ 18 from a previous price target of $14 .The Rating was issued on Apr 11, 2016.Depomed Inc is Initiated by Northland Capital to Outperform. The Rating was issued on Mar 24, 2016.Depomed Inc is Reiterated by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 14 from a previous price target of $16 . The Rating was issued on Mar 24, 2016.Depomed Inc is Initiated by Leerink Partners to Outperform and the brokerage firm has set the Price Target at $21. The Rating was issued on Mar 10, 2016.
Depomed Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Companys products include Gralise (gabapentin) CAMBIA (diclofenac potassium for oral solution) Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor a liquid filled capsule is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Companys product DM-1992 has completed a Phase II trial for Parkinson’s disease.